Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

The user switched from Pyrilutamide to RU58841, changed their Minoxidil solution, and continued using low-dose Finasteride, derma rolling, and specific shampoo. They asked others about their plans after Pyrilutamide's disappointing results.

The user is seeking a quicker-drying carrier for RU58841 and Minoxidil to improve adherence to their hair loss treatment routine. They want to apply it after a morning shower without affecting their hair's appearance.

User is experiencing issues with Minoxidil and is considering switching to Redensyl, specifically asking for brand recommendations. The Ordinary - Multi Peptide is mentioned, but the user seeks other brand experiences.

Redensyl is being compared to Minoxidil for hair loss treatment. Users discuss the effectiveness of Redensyl versus Minoxidil, with no clear consensus on which is better.

The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.

User asks about Redensyl as a substitute for Minoxidil due to side effects. Another user suggests trying Ordinary Hair Serum with dermarolling for improved hair quality.

The user has been using finasteride for 7 months and is inquiring about Thrive's hair serum, which contains redensyl, procapil, and anagain, seeking feedback from others who have used it.

The conversation is about different treatments for hair loss, including minoxidil, finasteride, RU58841, and dermarolling. The conclusion is that RU58841 and dermarolling have shown efficacy in treating hair loss through different pathways.

A new product, a retinoic acid solution (0.3%), is available to enhance minoxidil products like Rogaine and Kirkland by converting them into a tretinoin-containing solution for improved hair loss treatment. One unit of the product is enough for a year's supply.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation discusses the differences between Minoxidil and Redensyl for hair loss treatment. It also questions why Redensyl isn't as commonly discussed despite claims of its effectiveness.

Hair loss discussion mentions Minoxidil, Finasteride, and RU58841. User seeks opinions on Redensyl for hair regrowth and safety.

The user experienced significant hair regrowth with finasteride but stopped due to libido issues. They are now considering using minoxidil, dermarolling, and Nizoral to maintain their hairline.

A user is seeking a hair loss formula containing Redensyl and Capixyl without caffeine, Saw Palmetto, or other herbs. They want recommendations for such a product.

The user is considering using Ruderma to maintain hair and is concerned about potential hair loss acceleration due to starting TRT. They are also inquiring about the use of minoxidil, RU58841, and a derma roller for hair maintenance.

User experienced shedding and bald spots after 1 month of using Redensyl. Considering trying CosmeRNA as alternative treatment.

The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The conversation discusses the safety and effectiveness of continuing or adding RU58841 after stopping finasteride for hair loss treatment. One user expresses skepticism about using RU58841 due to the lack of full human trials.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The user had been using Minoxidil and Dutasteride with micro-needling but experienced hair loss after switching Minoxidil brands. Their doctor prescribed oral Minoxidil and Tretinoin, but the pharmacist suggested isotretinoin might be a more cost-effective alternative.

A user's progress with finasteride and dermarolling to regrow their hairline, with other users noting the improvement.

Pyrilutamide is seen as a last hope for those who can't take finasteride, with promising results reported. However, there's uncertainty about the quality and consistency of Pyrilutamide from black market sources.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.